secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001193125-24-258540
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero Q3 net loss widens to $17.1M; SPR720 halted after Phase 2a miss
---------------------------------------------------------------------

- Q3 net loss of $17.1M ($0.32 EPS) vs $3.2M loss a year ago; revenue fell 47% to $13.5M.
- Phase 3 PIVOT-PO trial of tebipenem HBr on track to complete enrollment in 2H 2025 (target ~2,648 patients).
- SPR720 program suspended after Phase 2a missed primary endpoint; three cases of reversible grade 3 hepatotoxicity.
- Cash and equivalents $76.3M; Oct 2024 restructuring and ~39% RIF extend cash runway into mid-2026.
- SPR206 IND cleared for Phase 2 in HABP/VABP, but initiation contingent on non-dilutive funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312524258540/0001193125-24-258540-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312524258540/d915138d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-258540

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer